Endocrinology
RSSArticles
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin to placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin vs. placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Thyroid Problems Could Raise Dementia Risk
Researchers recently observed an association between hypothyroidism and dementia.
-
Tirzepatide Injection (Mounjaro)
Tirzepatide can be prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-
Beware the Cardiovascular Risks Associated with Thyroid Hormone Replacement Therapy
Thyroid levels outside the euthyroid range have been associated with higher cardiovascular risk in patients taking thyroid hormone to treat hypothyroidism. In this study, a higher cardiovascular mortality rate was associated with exogenous hyperthyroidism and exogenous hypothyroidism.
-
Extend Life Expectancy by Achieving Type 2 Diabetes Therapeutic Goals
Investigators analyzed gains in life expectancy by achieving treatment goals, finding significant gains from lower body mass index, glycated hemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol.
-
Treatment Indication for Diabetes Drug Expanded to Include Heart Failure
FDA approves empagliflozin to help lower risk of hospitalization, death among heart failure patients.
-
Gestational Diabetes Risk May Be Higher Earlier in Pregnancy for Women with Sleep-Disordered Breathing
Screening and treatment might need to begin much earlier for these patients.
-
CT Scans Rarely Change Management of Acute Pancreatitis
For acute pancreatitis patients, efficient and clinically accurate triage is the singular most vital function to help eliminate potential claims — but more importantly, to provide safe and effective treatment to ED patients.
-
Combined GIP/GLP-1 Agonist: Safe for Type 2 Diabetes Patients?
In the SURPASS-2 trial, tirzepatide showed noninferiority and superiority vs. semaglutide in decreasing A1c levels in patients with type 2 diabetes.